Savolitinib

5 trials

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

0 Recruiting

5 Completed trials

2 Sponsors

12 Countries

Phase III

Phase II

Phase III: 2 Phase II: 3

Indications tested

Clear cell papillary renal cell carcinoma 1 Non-small cell lung cancer recurrent 1 Non-small cell lung cancer 1

Sponsors using this IMP

AstraZeneca AB 4 Centre Hospitalier Regional De Marseille 1

All trials

5 total

A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung c… Ended

2024-511169-12-00 Phase III 9 countries AstraZeneca AB
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET Driven, Unresectable and Locally Advanced or Metastatic PRCC … Ended

2022-503105-38-00 Phase III 8 countries AstraZeneca AB
A trial to learn how well osimertinib with savolitinib works in people with non-small cell lung cancer (NSCLC) that has gotten worse after i… Ended

2024-512581-34-00 Phase II 1 country AstraZeneca AB
A trial to learn how well osimertinib with savolitinib works in people with non-small cell lung cancer (NSCLC) that has gotten worse after i… Ended

2024-512564-58-00 Phase II 2 countries AstraZeneca AB
Precision Immuno-Oncology for advanced Non-small cell lung cancer patients with PD-1 ICI Resistance (PIONeeR clinical study) Ended

2024-515532-72-00 Phase II 1 country Centre Hospitalier Regional De Marseille

Showing 1–5 of 5 trials

← All drugs A–Z